“Knocking on the door of the ASX 100”: ACL makes $1.58b bid for healthcare giant Healius
Australian Clinical Labs (ASX: ACL) has lobbed a $1.58 billion off-market offer to merge with one of its biggest competitors, Healius (ASX: HLS), as it looks to become the nation's largest pathology services provider and secure a deal that could have it "knocking on the door of the ASX 100".
While ACL is the smaller of the two - with a market capitalisation of $726.6 million prior to its proposal - the Melbourne-based player believes it can help its larger rival turn around its operations, which posted a net profit loss of $28.7 million and earnings loss of $13.2 million in 1HFY23.
If the deal goes through, the combined entity will have 171 labs and 3,413 collection centres across the country, with expectations they will save up to $95 million over the next four years under the proposed combination of their labs, logistics, procurement benefits, back-office activities and overlapping IT systems.
Comments
Post a Comment